Synthesis of 9-anilinoacridine triazines as new class of hybrid antimalarial agents

Bioorganic and Medicinal Chemistry Letters

Volumn 19, Issue 24, 2009, Pages 6996-6999

  Kumar, Ashok ^a   Srivastava, Kumkum ^a   Raja Kumar, S ^a   Puri, S K ^a   Chauhan, Prem M S ^a  

^a CENTRAL DRUG RESEARCH INSTITUTE   (India)

Author keywords

9 Anilinoacridine triazine; Antimalarial; Plasmodium falciparum

Indexed keywords

6,9 DICHLORO 2 METHOXYACRIDINE; 9 ANILINOACRIDINE TRIAZINE DERIVATIVE; ACRIDINE DERIVATIVE; ANTIMALARIAL AGENT; CHLOROQUINE; CYANURIC ACID; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMALARIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SELECTIVITY; DRUG SYNTHESIS; IC 50; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII; PLASMODIUM YOELII INFECTION; VERO CELL;

AMSACRINE; ANIMALS; ANTIMALARIALS; MICE; PLASMODIUM FALCIPARUM; TRIAZINES;

MUS; PLASMODIUM FALCIPARUM; PLASMODIUM YOELII;

EID: 71949092011     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2009.10.010     Document Type: Article

References (41)

1. Kumar A., Katiyar S.B., Agarwal A., and Chauhan P.M.S. Curr. Med. Chem. 10 (2003) 1137
2. Kumar A., Katiyar S.B., Agarwal A., and Chauhan P.M.S. Drugs Future 28 (2003) 243
3. Frevert U. Trends Parasitol. 20 (2004) 417
4. Towie N. Nature 440 (2006) 852
5. White N.J. Lancet 353 (1999) 1965
6. Ridley R.G. Nature 415 (2002) 686
7. Chen C., Tang L.H., and Jantanavivat C. Trans. R. Soc. Trop. Med. Hyg. 86 (1992) 7
8. Obexar W., Schmid C., Barbe C., Galy J.P., and Brun R. Trop. Med. Parasitol. 46 (1995) 49
9. Girault S., Grellier P., Bereciber A., Maes L., Mouray E., Lemiere P., Debreu M.A., David-charvet E., and Sergheraert C. J. Med. Chem. 43 (2000) 2646
10. Rouvier C.S., Pradines B., Berthelot M., Parzy D., and Brabe J. Eur. J. Med. Chem. 39 (2004) 735
11. Chibale K., Haupt H., Kendrick H., Yardley V., Saravanamuthu A., Fairlamb A.H., and Croft S.L. Bioorg. Med. Chem. 11 (2001) 2655
12. Su T.L., Lin Y.W., Chou T.C., Zhang X., Bacherikov V.A., Chen C.H., Fiu L.F., and Tsai T.J. J. Med. Chem. 49 (2006) 3710l
13. Baguley B.C., Denny W.A., Atwell g.A., and Cain B.F. J. Med. Chem. 24 (1981) 170
14. May B.C.H., Witkop J., Sherrill J., Anderson M.O., Madrid P.B., Zorn J.A., Prusiner S.B., Cohen F.E., and Guy R.K. Bioorg. Med. Chem. Lett. 16 (2006) 4913
15. Fang L., Appenroth D., Decker M., Kiehntopf M., Roegler C., Deuful T., Fleck C., Peng S., Zhang Y., and Lehmann J. J. Med. Chem. 51 (2008) 713
16. Gamage S.A., Figgitt D.P., Wojcik S.J., Ralph R.K., Ransijn A., Maul J., Yardley V., Snowdon D., Croft S.L., and Denny W.A. J. Med. Chem. 40 (1997) 2634
17. Chen T.K., Fico R., and Genellakis E.S. J. Med. Chem. 21 (1978) 868
18. Dorn A., Vippagunta S.R., Matile H., Jaquet C., Vennertsom J.L., and Ridley R.G. Biochem. Pharmacol. 55 (1998) 727
19. Gamage S.A., Tepsiri N., Wilairat P., Wojcik S.J., Figgitt D.P., Ralph R.K., and Denny W.A. J. Med. Chem. 37 (1994) 1486
20. Chiyanzu I., Clarkson C., Smith P.J., Lehman J., Gut J., Rosenthal P.J., and Chibale K. Bioorg. Med. Chem. 13 (2005) 3249
21. Gupta L., Srivastava K., Singh S., Puri S.K., and Chauhan P.M.S. Bioorg. Med. Chem. Lett. 18 (2008) 3306
22. Singh C., Malik H., and Puri S.K. Bioorg. Med. Chem. 12 (2004) 1177
23. Dechy-Cabaret O., Benoit-Vical F., Robert A., and Meunier B. ChemBioChem 1 (2000) 281
24. Beagley P., Blackie M.A.L., Chibale K., Clarkson C., Meijboom R., Moss J.R., Smith P.J., and Su H. Dalton Trans. 15 (2003) 3046
25. Flipo M., Florent I., Grellier P., Sergheraert C., and Deprez-Poulain R. Bioorg. Med. Chem. Lett. 13 (2003) 2659
26. Cunico W., Cechinel C.A., Bonacorso H.G., Martins M.A.P., Zonatta N., Desouza M.V.N., Freitas I.O., Soares R.P.P., and Krettli A.U. Bioorg. Med. Chem. Lett. 16 (2006) 649
27. Opsenica I., Opsenica D., Lanteri C.A., Anova L., Milhous W.K., Smith K.S., and Salaja B.A. J. Med. Chem. 51 (2008) 6216
28. Gemma S., Campiani G., Butini S., Joshi B.P., Kukreja G., Coccone S.S., Burrutti M., Persico M., Nacci V., Fiorini I., Novellino E., Taramerlli D., Banilico N., Parapini S., Yardley V., Croft S., Maerk S.K., Rottman M., Brun R., Coletta M., Marini S., Guiso G., Caccia S., and Fattorusso C. J. Med. Chem. 52 (2009) 502
29. Kelly J.X., Smilkstein M.J., Brun R., Wittlin S., Cooper R.A., Lane K.D., Janowsky A., Johnson R.A., Dodean R.A., Winter R., Hinrichs D.J., and Riscoe M.K. Nature 14 (2009) 270
30. Smith C.C., Ihrig J., and Menne R. Am. J. Trop. Med. Hyg. 10 (1961) 694
31. Watkins W.M., Sixsmith D.G., and Chulay J.D. Ann. Trop. Med. Parasitol. 78 (1984) 273
32. Kinyanjui S.M., Mberu E.K., Winstanley P.A., Jacobus D.P., and Watkins W.M. Am. J. Trop. Med. Hyg. 60 (1999) 943
33. Guan J., Wang X., Smith K., Ager A., Gettayacamin M., Kyle D.E., Milhous W.K., Kozar M.P., Magill A.J., and Lin A.J. J. Med. Chem. 50 (2007) 6226
34. Agarwal A., Srivastava K., Puri S.K., and Chauhan P.M.S. Bioorg. Med. Chem. Lett. 15 (2005) 531
35. Katiyar S.B., Srivastava K., Puri S.K., and Chauhan P.M.S. Bioorg. Med. Chem. Lett. 15 (2005) 4957
36. Kumar A., Srivastava K., Raja Kumar S., Puri S.K., and Chauhan P.M.S. Bioorg. Med. Chem. Lett. 18 (2008) 6530
37. Hoglund I.P.J., Silver S., Engstrom M.J., Salo H., Tauber A., Kyyronem H.K., Saarenketo P., Hoffren A.M., Kokko K., Pohjanoksa K., Sallinen J., Savola J.M., Wurster S., and Kallatsa O.A. J. Med. Chem. 49 (2006) 6351
38. 9O: C, 63.51; H, 5.01; N, 20.20. Found: C, 63.42; H, 5.13; N, 20.03.
39. 50) was determined using non-linear regression analysis dose-response curves. Smilkstein M., Sriwilaijaroen N., Kelly J.X., Wilairat P., and Riscoe M. Antimicrob. Agents Chemother. 48 (2004) 1803
40. 50) was determined using non-linear regression analysis dose-response curves and represented the concentration of compound required to kill 50% of the fibroblast cells. Mosmann T. J. Immunol. Methods 65 (1983) 55
41. 6 parasitized RBC on day 0 and treatment was administered to a group of five mice from day 0 to 3, once daily. The aqueous suspensions of compounds were prepared with a few drops of Tween 80. The efficacy of test compounds was evaluated at 100 mg/kg/day and required daily dose was administered in 0.1 ml volume via oral route. Parasitaemia levels were recorded from thin blood smears between days 4 and 6. The mean value determined for a group of five mice was used to calculate the percent suppression of parasitaemia with respect to the untreated control group. Mice treated with CQ served as reference controls. Puri S.K., and Singh N. Expl. Parasitol. 94 (2000) 8